People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.
The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.
Findings from a meta-analysis indicate that Asian people may derive greater cardiovascular benefit from SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists than their White counterparts.
Real-world study results suggest that people with type 2 diabetes treated with insulin monotherapy have worse clinical outcomes than those given combination treatment with insulin and other antidiabetic drugs.
Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.
Older individuals with type 2 diabetes have a high risk for frailty, and risk predictors include poor glycemic control, depressive symptoms, and lifestyle factors, suggest findings from a Chinese cross-sectional study.
People with type 2 diabetes, particularly those diagnosed at a young age, can face an extended wait for medication to treat cardiovascular risk factors, even if they are in a high-risk category, research shows.
Integrating a comprehensive management plan into the World Health Organization maternal care framework has the potential to improve pregnancy outcomes for women with type 1 diabetes, suggest findings from the CARNATION study.
Routine psychosocial screening of adolescents with type 1 diabetes uncovers a sizable proportion who could benefit from additional support, say researchers.
Single-step screening for gestational diabetes makes twice the number of diagnoses of the two-step approach without resulting in better outcomes for women and infants, shows the randomized ScreenR2GDM trial.
A random blood glucose test in people without diabetes may provide a good indication of who has an increased risk for developing cardiovascular disease over the subsequent decade, a study suggests.
Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.
Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.
Dapagliflozin offers significant protection against worsening heart failure or cardiovascular death within 28 days of initiation, shows further analysis of DAPA-HF.
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.
Early findings suggest a novel molecule that selectively targets hepatic glucokinase may improve glucose control and reduce acute complication risk in people with type 1 diabetes.
Findings from a modeling study suggest that community-based exercise and cognitive behavioral therapy interventions for depression in people with type 2 diabetes are cost-effective in the long-term.
Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.